Clinical Trials Using Glucarpidase

Clinical trials are research studies that involve people. The clinical trials on this list are studying Glucarpidase. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma

    This early phase I trial studies how well glucarpidase works in treating patients with central nervous system B-cell non-Hodgkin lymphoma. Glucarpidase is a type of bacterial enzyme that breaks down proteins and other substances. It may also help activate certain drugs to kill cancer. Giving glucarpidase may work better in treating patients with central nervous system B-cell non-Hodgkin lymphoma.
    Location: 8 locations

  • Glucarpidase after High-Dose Methotrexate in Patients with Osteosarcoma

    This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients’ blood and lead to shorter hospitalizations and a reduction in toxicities.
    Location: 3 locations

  • Glucarpidase for the Improvement of Methotrexate Toxicity and Detection in Central Nervous System Involvement of Aggressive Lymphoma

    This phase II trial studies the effect of glucarpidase in improving methotrexate toxicity and detection in patients with central nervous system involvement of aggressive lymphoma. Patients with aggressive lymphomas who are at high risk of their cancer spreading to the brain and / or spinal cord or are found to have spread to the brain and / or spinal cord are often recommended to receive an additional chemotherapy drug, called methotrexate, as part of their treatment course. High-dose methotrexate is given because it is able to penetrate the brain and spinal cord more effectively than the other standard chemotherapy drugs used for lymphoma. Normally, methotrexate is administered intravenously over 4 hours followed by administration of intravenous fluids and a medication called leucovorin which both help clear the methotrexate from the body. Patients are discharged from the hospital once the methotrexate has cleared and side effects from methotrexate, if any, are resolved or improved. However, patients who are older or have a history of kidney disease are at higher risk for side effects associated with methotrexate and often require a longer time to clear the methotrexate out of the body. Patients who have a prolonged time to clear methotrexate or who have kidney damage caused by methotrexate are candidates to receive an antidote, called glucarpidase (carboxypeptidase G2), which may help to clear methotrexate more quickly form the body.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania